Loading...
Market
Will BioAge Labs' azelaprag receive Fast Track designation from the FDA by September 26, 2025?
2
Resolution / Starting Odds
Yes • 25%
No • 25%
Application submitted but not yet approved • 25%
Not applicable/Other • 25%
FDA announcements or official press releases from BioAge Labs
Story
BioAge Labs Raises $198M in Upsized IPO at $18 Midpoint for Obesity Drug Research
Sep 26, 2024, 03:40 AM
BioAge Labs, a weight-loss drug developer, has successfully raised $198 million through its upsized U.S. initial public offering (IPO), pricing its shares at the midpoint of $18 each. The company aims to use the funds to advance its anti-obesity drug research, particularly focusing on its muscle-building obesity drug candidate, azelaprag. The IPO was upsized again due to increased demand, reflecting investor confidence in BioAge Labs' pivot to obesity drug research.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
